How to Invest in Neuropace?
Neuropace Investing Guide | NPCE |
- Research Neuropace's stock before investing in Neuropace. It's a good idea to research the company and its stock by analyzing its financial statements, reading news articles, and studying its historical performance, including its growth strategy, change in net worth, competition, and potential risks.
- Choose a brokerage firm to buy shares of Neuropace. We recommend well-established brokerages such as Charles Schwab, Fidelity, TD Ameritrade, and Robinhood, but in many ways, it will depend on your individual needs, preferences, and investment goals.
- Open an account at one of the brokerages you have selected. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account. You will need to deposit funds into your brokerage account to purchase Neuropace stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order. Once you have located Neuropace stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock.
It's important to note that investing in stocks such as Neuropace carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions regarding Neuropace Stock. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to invest safely in Neuropace.
Research Neuropace Stock
Researching Neuropace's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E).
About 83.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 0.98. Neuropace had not issued any dividends in recent years. NeuroPace, Inc. operates as a medical device company in the United States. The company was incorporated in 1997 and is headquartered in Mountain View, California. Neuropace operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 187 people. To find out more about Neuropace contact Michael Favet at 650 237 2700 or learn more at https://www.neuropace.com. Other things to consider when investing in Neuropace
Another important aspect of Neuropace's research is to evaluate the company's potential for future growth. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Neuropace's research are outlined below:
| Neuropace had very high historical volatility over the last 90 days | |
| Neuropace has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 65.42 M. Net Loss for the year was (32.96 M) with profit before overhead, payroll, taxes, and interest of 32.49 M. | |
| Neuropace currently holds about 92.41 M in cash with (19.7 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.72. | |
| Neuropace has a frail financial position based on the latest SEC disclosures | |
| Over 83.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: NeuroPace, Inc. Reports Q3 Loss, Tops Revenue Estimates - MSN |
Neuropace Quarterly Cash And Short Term Investments |
|
Check Neuropace's earnings reports
Neuropace uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Neuropace. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Neuropace's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 7th of March 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 7th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Use historical earnings surprises to time your Neuropace position
Earnings surprises can significantly impact Neuropace's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Neuropace's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-08-13 | 2024-06-30 | -0.3 | -0.26 | 0.04 | 13 | ||
2021-11-10 | 2021-09-30 | -0.3 | -0.34 | -0.04 | 13 | ||
2023-05-04 | 2023-03-31 | -0.46 | -0.41 | 0.05 | 10 | ||
2024-11-12 | 2024-09-30 | -0.27 | -0.19 | 0.08 | 29 | ||
2024-03-05 | 2023-12-31 | -0.31 | -0.23 | 0.08 | 25 | ||
2022-08-11 | 2022-06-30 | -0.44 | -0.52 | -0.08 | 18 | ||
2023-08-08 | 2023-06-30 | -0.46 | -0.36 | 0.1 | 21 | ||
2022-03-10 | 2021-12-31 | -0.33 | -0.44 | -0.11 | 33 |
Know Neuropace's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Neuropace is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Neuropace backward and forwards among themselves. Neuropace's institutional investor refers to the entity that pools money to purchase Neuropace's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Northern Trust Corp | 2024-09-30 | 159.8 K | State Street Corp | 2024-06-30 | 142.6 K | Renaissance Technologies Corp | 2024-09-30 | 87 K | Man Group Plc | 2024-06-30 | 38.5 K | Citadel Advisors Llc | 2024-06-30 | 37.1 K | Charles Schwab Investment Management Inc | 2024-09-30 | 36.5 K | Bank Of New York Mellon Corp | 2024-06-30 | 34.1 K | Bridgeway Capital Management, Llc | 2024-06-30 | 33.2 K | Two Sigma Investments Llc | 2024-06-30 | 33.1 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 4.9 M | Orbimed Advisors, Llc | 2024-06-30 | 3.4 M |
Follow Neuropace's market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 274.3 M.Market Cap |
|
Evaluate Neuropace's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.31) | (0.32) | |
| Return On Capital Employed | (0.30) | (0.31) | |
| Return On Assets | (0.31) | (0.32) | |
| Return On Equity | (1.60) | (1.52) |
Determining Neuropace's profitability involves analyzing its financial statements and using various financial metrics to assess its ability to generate profits. Also, when deciding whether to invest in Neuropace, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Neuropace's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Neuropace's profitability and make more informed investment decisions.
Please note, the presentation of Neuropace's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Neuropace's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Neuropace's management manipulating its earnings.
Evaluate Neuropace's management efficiency
Neuropace has return on total asset (ROA) of (0.1474) % which means that it has lost $0.1474 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.1455) %, meaning that it created substantial loss on money invested by shareholders. Neuropace's management efficiency ratios could be used to measure how well Neuropace manages its routine affairs as well as how well it operates its assets and liabilities. As of November 22, 2024, Return On Tangible Assets is expected to decline to -0.32. In addition to that, Return On Capital Employed is expected to decline to -0.31. At present, Neuropace's Other Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Asset Turnover is expected to grow to 0.85, whereas Non Current Assets Total are forecasted to decline to about 7.5 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.80 | 0.84 | |
| Tangible Book Value Per Share | 0.80 | 0.84 | |
| Enterprise Value Over EBITDA | (14.05) | (14.75) | |
| Price Book Value Ratio | 12.90 | 13.55 | |
| Enterprise Value Multiple | (14.05) | (14.75) | |
| Price Fair Value | 12.90 | 13.55 | |
| Enterprise Value | 320.9 M | 433.9 M |
Neuropace showcases strong leadership that adapts to market changes and drives innovation. Our analysis explores how this adaptability affects the stock's investment appeal.
Beta 1.798 |
Basic technical analysis of Neuropace Stock
As of the 22nd of November, Neuropace secures the Downside Deviation of 3.6, mean deviation of 3.45, and Risk Adjusted Performance of 0.0778. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Neuropace, as well as the relationship between them. Please verify Neuropace value at risk, as well as the relationship between the semi variance and kurtosis to decide if Neuropace is priced some-what accurately, providing market reflects its recent price of 9.0 per share. Given that Neuropace has jensen alpha of 0.2661, we recommend you to check Neuropace's last-minute market performance to make sure the company can sustain itself at a future point.Check Neuropace's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Neuropace insiders, such as employees or executives, is commonly permitted as long as it does not rely on Neuropace's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Neuropace insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Evaluate Neuropace's Outstanding Corporate Bonds
Neuropace issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Neuropace uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Neuropace bonds can be classified according to their maturity, which is the date when Neuropace has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Neuropace's technical indicators
Using predictive indicators to make investment decisions involves analyzing Neuropace's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0778 | |||
| Market Risk Adjusted Performance | 0.1997 | |||
| Mean Deviation | 3.45 | |||
| Semi Deviation | 3.18 | |||
| Downside Deviation | 3.6 | |||
| Coefficient Of Variation | 1089.33 | |||
| Standard Deviation | 5.38 | |||
| Variance | 28.96 | |||
| Information Ratio | 0.0741 | |||
| Jensen Alpha | 0.2661 | |||
| Total Risk Alpha | (0.13) | |||
| Sortino Ratio | 0.1109 | |||
| Treynor Ratio | 0.1897 | |||
| Maximum Drawdown | 35.38 | |||
| Value At Risk | (6.19) | |||
| Potential Upside | 9.73 | |||
| Downside Variance | 12.93 | |||
| Semi Variance | 10.11 | |||
| Expected Short fall | (4.13) | |||
| Skewness | 2.42 | |||
| Kurtosis | 10.09 |
| Risk Adjusted Performance | 0.0778 | |||
| Market Risk Adjusted Performance | 0.1997 | |||
| Mean Deviation | 3.45 | |||
| Semi Deviation | 3.18 | |||
| Downside Deviation | 3.6 | |||
| Coefficient Of Variation | 1089.33 | |||
| Standard Deviation | 5.38 | |||
| Variance | 28.96 | |||
| Information Ratio | 0.0741 | |||
| Jensen Alpha | 0.2661 | |||
| Total Risk Alpha | (0.13) | |||
| Sortino Ratio | 0.1109 | |||
| Treynor Ratio | 0.1897 | |||
| Maximum Drawdown | 35.38 | |||
| Value At Risk | (6.19) | |||
| Potential Upside | 9.73 | |||
| Downside Variance | 12.93 | |||
| Semi Variance | 10.11 | |||
| Expected Short fall | (4.13) | |||
| Skewness | 2.42 | |||
| Kurtosis | 10.09 |
Consider Neuropace's intraday indicators
Neuropace intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Neuropace stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 2256.89 | |||
| Daily Balance Of Power | (0.41) | |||
| Rate Of Daily Change | 0.98 | |||
| Day Median Price | 8.99 | |||
| Day Typical Price | 8.99 | |||
| Price Action Indicator | (0.09) | |||
| Period Momentum Indicator | (0.19) |
Neuropace Corporate Filings
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
8K | 12th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 4th of November 2024 Other Reports | ViewVerify | |
F4 | 28th of October 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
Choose a brokerage platform to buy Neuropace's shares
In investing, finding the right broker is a crucial step for anyone looking to embark on a journey into the stock market. It all begins with a thorough comparison of costs and fees, as low-cost or commission-free brokers can significantly impact an investor's returns. However, the cheapest option is not always the best choice. The adventure continues with exploring various trading platforms, seeking one that is user-friendly, reliable, and functional. The ideal platform will provide the necessary research, analysis, and investment monitoring tools. As the quest goes on, it's essential to consider the different account types brokers offer, such as individual, joint, and retirement accounts. In addition, for those interested in trading on margin, brokers offering margin accounts should also be considered. The journey leads to the discovery of brokers that provide a wide range of investment options, including stocks, bonds, ETFs, and mutual funds. This diversity allows investors to build well-rounded portfolios that suit their needs and goals. Customer service is another crucial factor in this decision-making process. The perfect broker would have a responsive, knowledgeable, and available customer support team ready to assist with various issues or investment decisions. Aspiring investors should seek brokers with quality research, market analysis, and educational resources. These tools are essential for making informed decisions and improving investment knowledge. It's also vital to ensure that the broker is regulated by an appropriate regulatory body and has robust security measures to protect personal and financial information. Additionally, account minimums and funding options should be taken into consideration. A broker with flexible account minimums and various funding options, such as wire transfers, ACH transfers, or check deposits, will cater to different investor needs. A seamless mobile and web experience is a must in today's fast-paced world. The ideal broker will allow investors to manage their investments easily on the go. Finally, it is essential to consider various brokers' reviews and conduct reputation analysis. By reading online assessments and seeking recommendations, valuable insights into each broker's reputation can be gathered. After a thorough investigation, you can find a broker that checks all the boxes and aligns with their preferences and requirements regarding taking a position in Neuropace.
Open brokerage account to buy Neuropace Stock
Once you've selected a broker, visit their website or a local branch to initiate the account-opening process. Most brokers offer online account opening, which is typically faster and more convenient. When you begin the process, you'll need to select the type of account you want to open. This may include individual, joint, or retirement accounts. Some brokers may also offer margin accounts, which allow you to trade on margin. Next, you'll need to complete the application form. Whether you're filling out an online or paper application, you'll need to provide personal information, such as your name, address, Social Security Number or other tax identification number, date of birth, and employment information. You may also be asked about your investment experience, financial situation, and goals. After completing the application form, review it carefully for accuracy and submit it to the broker. Some brokers may require you to provide additional documentation, such as a copy of your driver's license or passport, for identity verification. Once your application is submitted, the broker will review it and may run a background check or verify your credit history. You'll receive an email or notification with your new brokerage account details if your application is approved.
Fund your account to invest in Neuropace Stock
Once your account is open, you can fund it by linking your bank account to your brokerage account. To do this, log in to your brokerage account and look for an option to add or link a bank account. You will need to provide your bank account number and the routing number for your bank. This information can be found on your checks or by contacting your bank. After linking your bank account, you can initiate a transfer of funds from your bank account to your brokerage account. This process may vary depending on the brokerage, but generally, you will need to navigate to the funding or deposit section of the brokerage website or app. From there, you can choose the linked bank account and enter the amount you wish to transfer. Keep in mind that there may be limits on the amount you can transfer in a single transaction, and the transfer may take several business days to complete. Some brokerages also offer other funding options, such as wire transfers, mailing a check, or transferring assets from another brokerage. If you prefer to use one of these methods, check with your brokerage firm for specific instructions. Once the funds are in your brokerage account, you can use them to purchase investments such as stocks, bonds, mutual funds, or other financial instruments.
Place your Neuropace Stock order
Placing a Neuropace purchase order involves providing instructions to your selected brokerage firm to aquare shares of Neuropace on your behalf. First, your will need to access your brokerage account through their website or mobile app using your login credentials. Make sure you have sufficient funds in your account to cover the cost of the stock purchase, including any applicable fees or commissions. Once you are logged in, locate the trading platform or order entry section within the brokerage interface. It may be labeled as "Trade," "Order Entry," or something similar. Next, you will need to provide the necessary information to place your stock order. This typically includes: .
After entering the necessary information, review your order carefully to ensure it reflects your intentions accurately. When you are ready, submit your order by clicking the "Submit," "Place Order," or equivalent button. Your brokerage firm will then execute your order according to your instructions, subject to market conditions and the availability of shares. Keep in mind that market orders may be executed immediately, while limit orders, stop orders, and stop-limit orders will only be executed if the specified conditions are met. Finally, monitor your order status and confirm its execution. You can usually find this information in the "Order History" or "Order Status" section of your brokerage account.
| Ticker | Enter the ticker symbol, which is the unique series of letters representing the stock, e.g., NPCE for Neuropace | |
| Type | Choose the type of order you want to place. The most common order types are market orders, limit orders, stop orders, and stop-limit orders. Each order type has its own advantages and drawbacks, so be sure to research and understand them before placing your order. | |
| Quantity | Specify the number of shares you want to buy or sell | |
| Duration | Indicate the duration for which your order will be active. You can choose from options like "Day" (valid only for the current trading day) or "Good 'til Canceled" (valid until you manually cancel the order) |
Monitor your Neuropace Stock position
Monitoring your stock positions with your brokerage involves regularly checking the status and performance of your investments. Here's how you can monitor your stock positions using your brokerage account: First, access your account by signing in to your brokerage firm's website or mobile app using your login credentials. Once you're logged in, look for the section that displays your account information and portfolio holdings. This section may be labeled as "Portfolio," "Positions," "Holdings," or something similar. In this section, you'll generally find a list of the stocks and other investments that you own, along with relevant details such as the number of shares, the current market value, and the percentage change in value since the last trading day's close. You might also see the total cost of your investment, your current profit or loss, and the percentage gain or loss. Many brokerages also provide tools and features that allow you to analyze and track your stock positions more effectively. These may include:
As you continue to monitor your Neuropace Stock position, remember that in order to be an effective trader, it is critical to understand your entire portfolio's sensitivity to market volatility and how your single Neuropace position affects your overall exposure to market risk. One of the techniques to manage your overall risk is pair trading, a market-neutral trading strategy enabling traders to profit from virtually any market condition, whether it is experiencing an uptrend or downtrend movement.
| Performance Charts | These charts visually represent the historical price movement of your stocks over different time frames. You can use them to assess the trends and volatility of your investments. | |
| Stock Alerts | You can set up custom alerts to receive notifications when a stock reaches a certain price, percentage change, or other criteria. This can help you stay informed about significant market movements affecting your investments. | |
| Watchlists | Create watchlists to track the performance of stocks you are interested in but have not yet purchased. This can help you identify potential opportunities or risks. | |
| Research Tools | Brokerages often provide access to research tools, such as stock screeners, analyst reports, and financial statements, to help you make more informed investment decisions. |
Moving together with Neuropace Stock
Moving against Neuropace Stock
| 0.64 | FIGS | Figs Inc | PairCorr |
| 0.5 | TFX | Teleflex Incorporated | PairCorr |
| 0.5 | GCTK | GlucoTrack | PairCorr |
| 0.43 | CVS | CVS Health Corp Aggressive Push | PairCorr |
Follow Neuropace Stock across various news and media outlets
Far too much social signal, news, headlines, and media speculation about Neuropace that are available to investors today. That information is available publicly through Neuropace media outlets and privately through word of mouth or via Neuropace internal channels. However, regardless of the origin, that massive amount of Neuropace data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Neuropace news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Neuropace relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Neuropace's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Neuropace alpha.